BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10602481)

  • 21. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma.
    Tomlinson JS; Alpaugh ML; Barsky SH
    Cancer Res; 2001 Jul; 61(13):5231-41. PubMed ID: 11431364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer.
    Ascaño JJ; Frierson H; Moskaluk CA; Harper JC; Roviello F; Jackson CE; El-Rifai W; Vindigni C; Tosi P; Powell SM
    Mod Pathol; 2001 Oct; 14(10):942-9. PubMed ID: 11598162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
    Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
    Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance.
    Chang HW; Chow V; Lam KY; Wei WI; Yuen A
    Cancer; 2002 Jan; 94(2):386-92. PubMed ID: 11900224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
    Macaluso M; Cinti C; Russo G; Russo A; Giordano A
    Oncogene; 2003 Jun; 22(23):3511-7. PubMed ID: 12789259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts.
    Le Mée S; Fromigué O; Marie PJ
    Exp Cell Res; 2005 Jan; 302(1):129-42. PubMed ID: 15541732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions.
    Chiles MC; Ai L; Zuo C; Fan CY; Smoller BR
    Mod Pathol; 2003 Oct; 16(10):1014-8. PubMed ID: 14559984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma.
    Zhang CY; Mao L; Li L; Tian Z; Zhou XJ; Zhang ZY; Li J
    Cancer; 2007 Jul; 110(1):87-95. PubMed ID: 17520682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer.
    Asgeirsson KS; Olafsdóttir K; Jónasson JG; Ogmundsdóttir HM
    Cytokine; 1998 Sep; 10(9):720-8. PubMed ID: 9770334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
    Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
    Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SLUG zinc-finger protein represses E-cadherin in breast cancer.
    Hajra KM; Chen DY; Fearon ER
    Cancer Res; 2002 Mar; 62(6):1613-8. PubMed ID: 11912130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells.
    Oesterreich S; Deng W; Jiang S; Cui X; Ivanova M; Schiff R; Kang K; Hadsell DL; Behrens J; Lee AV
    Cancer Res; 2003 Sep; 63(17):5203-8. PubMed ID: 14500345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells.
    van Horssen R; Hollestelle A; Rens JA; Eggermont AM; Schutte M; Ten Hagen TL
    Breast Cancer Res Treat; 2012 Nov; 136(2):365-77. PubMed ID: 23053649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory mechanisms controlling human E-cadherin gene expression.
    Liu YN; Lee WW; Wang CY; Chao TH; Chen Y; Chen JH
    Oncogene; 2005 Dec; 24(56):8277-90. PubMed ID: 16116478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro.
    Dong HM; Liu G; Hou YF; Wu J; Lu JS; Luo JM; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2007 Feb; 133(2):83-92. PubMed ID: 16932944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.
    Deng Y; Deng H; Liu J; Han G; Malkoski S; Liu B; Zhao R; Wang XJ; Zhang Q
    Mol Carcinog; 2012 Jun; 51(6):500-7. PubMed ID: 21681822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mechanism and significance of E-cadherin, anti-apoptosis B-cell lymphoma-2 protein and sE-cadherin roles in cancer.
    Liu L; Li HX; Lv XQ
    J Biol Regul Homeost Agents; 2014; 28(4):683-91. PubMed ID: 25620178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism?
    Fearon ER
    J Natl Cancer Inst; 2000 Apr; 92(7):515-7. PubMed ID: 10749897
    [No Abstract]   [Full Text] [Related]  

  • 40. Levels of soluble E-cadherin in breast, gastric, and colorectal cancers.
    Repetto O; De Paoli P; De Re V; Canzonieri V; Cannizzaro R
    Biomed Res Int; 2014; 2014():408047. PubMed ID: 25535613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.